Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
1,037
result(s) for
"Collins, Francis"
Sort by:
A New Initiative on Precision Medicine
President Obama has announced a research initiative that aims to accelerate progress toward a new era of precision medicine, with a near-term focus on cancers and a longer-term aim to generate knowledge applicable to the whole range of health and disease.
“Tonight, I'm launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer and diabetes — and to give all of us access to the personalized information we need to keep ourselves and our families healthier.”
— President Barack Obama, State of the Union Address, January 20, 2015
President Obama has long expressed a strong conviction that science offers great potential for improving health. Now, the President has announced a research initiative that aims to accelerate progress toward a new era of precision medicine (www.whitehouse.gov/precisionmedicine). We believe that the time is right for this visionary initiative, . . .
Journal Article
لغة الإله
يتحدث هذا الكتاب حول دليل الوجود الإلهي من خلال علم الاحياء والفيزياء الفلكية وعلم النفس وغيرها من التخصصات ويشير إلى العديد من المفكرين كالقديس أوغسطين وستيفن هوكينغ ويقترح الكتاب مفهوم (التصميم الإلهي الحيوي) والذي يسميه BioLogos ومن خلاله يعرب عن الاعتقاد بأن الله هو مصدر كل حياة وأن الحياة تعبر عن إرادة الله وأن العلم والإيمان هما وجهان لعملة واحدة.
Book
Realizing the Dream of Molecularly Targeted Therapies for Cystic Fibrosis
The diary entry of an 8-year-old girl with cystic fibrosis indicates that Aug. 25, 1989, was an important day for her (Figure 1). That was the day the research teams at the University of Michigan and the Hospital for Sick Children, Toronto, announced the discovery of the cystic fibrosis gene and the most common mutation, a three-base deletion that results in a missing phenylalanine in codon 508 (denoted the Phe508del
CFTR
mutation). We hoped that the gene discovery would someday lead to effective treatments for children and adults with cystic fibrosis, but we knew that would be a long road.
2,3
. . .
Journal Article
لغة الحياة : الحمض النووي والثورة في الطب الشخصي : تعتمد حياتك على أسرار حمضك النووي فهل أنت مستعد لهذا الأمر ؟
لقد اجتاحت حياتنا ثورة علمية وطبية، ففي الولايات المتحدة وحدها يعاني ستة آلاف شخص أمراضا نادرة، يعزى معظمها إلى خلل جيني أو الجينات الخطأ. عمليا تحدث جميع الأمراض بسبب مكون وراثي. وقد أخذت أمراض كثيرة، مثل السكري والقلب والسرطان والأمراض العقلية والربو وداء المفاصل والزهايمر، تتكشف أسرارها من خلال الحمض النووي. وقد بدأت عائلات كثيرة من التي واجهت مشكلات عامة، وكادت تفقد الأمل، تكتشف عالما جديدا من المعرفة والعلاج والوقاية، أنت مدين لنفسك لتعرف عن حمضك النووي : كيف يعمل وما يكشف، وما مزايا هذه المعرفة الجديدة وحدودها .كما أن ال د. فرانسيس كولينز ، من الرواد الباحثين في علم الجينات. قضى 15 عاما مديرا للمعهد الوطني لبحوث الجينوم البشري، حيث قاد مشروع الجينوم البشري العالمي إلى نهاية ناجحة. وتقديرا لمساهماته الثورية في البحوث الجينية، حصل على وسام الحرية عام 2007 م، والوسام الوطني للعلوم عام 2009 م، وهو مدير معهد الصحة الوطني الأمريكي.
Book
The Role of Science in Addressing the Opioid Crisis
The National Institutes of Health will work with private partners to develop better overdose-reversal and prevention interventions; find new medications and technologies to treat opioid addiction; and find safe, effective, nonaddictive strategies to manage chronic pain.
Journal Article
A strategic approach to COVID-19 vaccine R&D
A public-private partnership and platform for harmonized clinical trials aims to accelerate licensure and distribution There is an unprecedented need to manufacture and distribute enough safe and effective vaccine to immunize an extraordinarily large number of individuals in order to protect the entire global community from the continued threat of morbidity and mortality from severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2). The global need for vaccine and the wide geographic diversity of the pandemic require more than one effective vaccine approach. Collaboration will be essential among biotechnology and pharmaceutical companies, many of which are bringing forward a variety of vaccine approaches ( 1 ). The full development pathway for an effective vaccine for SARS-CoV-2 will require that industry, government, and academia collaborate in unprecedented ways, each adding their individual strengths. We discuss one such collaborative program that has recently emerged: the ACTIV (Accelerating COVID-19 Therapeutic Interventions and Vaccines) public-private partnership. Spearheaded by the U.S. National Institutes of Health (NIH), this effort brings together the strengths of all sectors at this time of global urgency. We further discuss a collaborative platform for conducting harmonized, randomized controlled vaccine efficacy trials. This mechanism aims to generate essential safety and efficacy data for several candidate vaccines in parallel, so as to accelerate the licensure and distribution of multiple vaccine platforms and vaccines to protect against COVID-19 (coronavirus disease 2019).
Journal Article
NIH to balance sex in cell and animal studies
Janine A. Clayton and Francis S. Collins unveil policies to ensure that preclinical research funded by the US National Institutes of Health considers females and males.
Journal Article
The Next Phase of Human Gene-Therapy Oversight
As gene therapy continues to change, so must the federal framework set up to oversee it. As new biotechnologies continue to emerge, the NIH and the FDA are proposing reductions in duplicative oversight and changes to the role of the Recombinant DNA Advisory Committee.
Journal Article
National Institutes of Health addresses the science of diversity
The US biomedical research workforce does not currently mirror the nation’s population demographically, despite numerous attempts to increase diversity. This imbalance is limiting the promise of our biomedical enterprise for building knowledge and improving the nation’s health. Beyond ensuring fairness in scientific workforce representation, recruiting and retaining a diverse set of minds and approaches is vital to harnessing the complete intellectual capital of the nation. The complexity inherent in diversifying the research workforce underscores the need for a rigorous scientific approach, consistent with the ways we address the challenges of science discovery and translation to human health. Herein, we identify four cross-cutting diversity challenges ripe for scientific exploration and opportunity: research evidence for diversity’s impact on the quality and outputs of science; evidence-based approaches to recruitment and training; individual and institutional barriers to workforce diversity; and a national strategy for eliminating barriers to career transition, with scientifically based approaches for scaling and dissemination. Evidence-based data for each of these challenges should provide an integrated, stepwise approach to programs that enhance diversity rapidly within the biomedical research workforce.
Journal Article